Seyoum Bage, MD
Infectious Disease · Marietta, OHNPI 1609842640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,126 and has fallen 93.2% since, to $76 in 2025.
Across 244 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Melinta Therapeutics, LLC$1K
- Gilead$724
- Insmed, Inc.$692
- AbbVie$562
- Viiv Healthcare Company$424
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$801%
- Food & beverage$5,36698%
- Education$461%
- Gifts$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 49 | $1,061 |
| Melinta Therapeutics, LLC | 37 | $1,001 |
| Gilead | 37 | $724 |
| Insmed, Inc. | 29 | $692 |
| AbbVie(2 entities) | 27 | $562 |
| Viiv Healthcare Company | 22 | $424 |
| Tetraphase Pharmaceuticals, Inc. | 8 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $160 |
| Shionogi Inc | 7 | $141 |
| Paratek Pharmaceuticals, Inc. | 7 | $125 |
| La Jolla Pharmaceutical Company | 4 | $87 |
| Organogenesis Inc. | 1 | $80 |
| Xeris Pharmaceuticals, Inc. | 1 | $53 |
| Theratechnologies Inc. | 3 | $46 |
| Johnson & Johnson | 2 | $43 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Accelerate Diagnostics Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,500 in reported general payments places this provider in the 85th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $156,845 |
| Daptomycin | 30 | $45,527 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $32,172 |
| TivicayDolutegravir Sodium | 12 | $26,426 |
| ErtapenemErtapenem Sodium | 13 | $8,255 |
| Vancomycin Hcl | 33 | $5,550 |
| Rifabutin | 12 | $5,344 |
| Cefepime Hcl | 21 | $5,045 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 20 | $4,746 |
| Methenamine Hippurate | 45 | $3,671 |
| Lamivudine HbvLamivudine | 12 | $2,261 |
| CeftriaxoneCeftriaxone Sodium | 25 | $1,651 |
| NitrofurantoinNitrofurantoin Macrocrystal | 33 | $1,014 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 38 | $942 |
| ValacyclovirValacyclovir Hcl | 17 | $893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $724 | $156,84537 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $424 | $58,59823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 infectious disease providers in Ohio.
Other infectious disease in Marietta
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
- Thomas FileAkron$68K
- Nelson NicolasoraToledo$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.